MedTrace Logo

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

NCT05674929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

Conditions

Interventions

DRUG

BPL-003

A single dose administered intranasally

Sponsors & Collaborators

  • Beckley Psytech Limited

    lead INDUSTRY

Principal Investigators

  • Kevin Craig, M.D. · Beckley Psytech Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2024-10-02
Completion
2024-10-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05674929 on ClinicalTrials.gov